アデノシンデアミナーゼ-重症複合免疫不全症の世界市場レポート 2025年

アデノシンデアミナーゼ-重症複合免疫不全症市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.6％で77億米ドルに成長します。予測期間中の成長は、遺伝性疾患の有病率の上昇、骨髄移植の利用の増加、非調整幹細胞移植の需要の増加、ADA欠損症の有病率の上昇、アデノシンデアミナーゼ欠損症（PDA）の症例数の増加によって牽引される可能性があります。この期間の主な動向としては、技術の進歩、遺伝子治療の採用、政府の取り組み、遺伝子検査の進歩、バイオテクノロジーの進歩などが挙げられます。

遺伝性疾患の有病率の増加は、アデノシンデアミナーゼ-重症複合免疫不全症（ADA-SCID）市場の成長を促進すると予想されます。遺伝性疾患は、個人のDNAの異常や変異に起因するものであり、遺伝性のもの、自然発生的なものがあります。診断技術の進歩、意識の向上、親の年齢の上昇、環境の影響、人口増加などの要因が、遺伝性疾患の有病率の上昇に寄与しています。特に、ADA-SCIDを含む遺伝性疾患の増加により、高度な診断技術や標的治療に対する需要が高まっています。例えば、2022年12月、英国の政府機関である保健社会医療省（DHSC）が発表した報告書によると、2022年10月現在、約3万3,000人分の全ゲノム配列が決定され、平均診断収率は32％で、特定の疾患では61％に上昇することが明らかになりました。その結果、遺伝性疾患の有病率の増加がADA-SCID市場の拡大を後押ししています。

ADA-SCID市場の主要企業は、患者の予後を改善し、生存率を向上させ、先進医療技術を使用して疾患の根本的な遺伝的原因に対処するために、遺伝子治療などの革新的な治療の開発を優先しています。ADA-SCIDの遺伝子治療は、ADA遺伝子の機能的コピーを導入することで遺伝的欠損を修正することを目的としており、このまれで生命を脅かす免疫疾患を長期的に治癒させる可能性があります。例えば、2022年5月、米国のライフサイエンス・診断企業であるダナハー社は、AMP（Accelerating Medicines Partnership）プログラムの一環として、BGTC（Bespoke Gene Therapy Consortium）に参加しました。このイニシアチブは、米国食品医薬品局（FDA）、米国国立衛生研究所（NIH）、製薬会社、非営利団体と協力し、希少疾患のためのオーダーメイド遺伝子治療を前進させ、その開発を合理化することを目指しています。この共同研究は、有病率が低いために商業的な関心が限定されがちな希少疾患に対する従来の医薬品開発の課題に取り組むものとして、特に重要です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界アデノシンデアミナーゼ-重症複合免疫不全症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のアデノシンデアミナーゼ-重症複合免疫不全症市場：成長率分析
• 世界のアデノシンデアミナーゼ-重症複合免疫不全症市場の実績：規模と成長, 2019-2024
• 世界のアデノシンデアミナーゼ-重症複合免疫不全症市場の予測：規模と成長, 2024-2029, 2034F
• 世界アデノシンデアミナーゼ-重症複合免疫不全症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のアデノシンデアミナーゼ-重症複合免疫不全症市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 酵素補充療法（ERT）
• 遺伝子治療
• 幹細胞移植
• 支持療法による治療
• 世界のアデノシンデアミナーゼ-重症複合免疫不全症市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内
• 皮下
• オーラル
• 世界のアデノシンデアミナーゼ-重症複合免疫不全症市場：年齢層別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小児科（乳児および小児）
• 大人
• 世界のアデノシンデアミナーゼ-重症複合免疫不全症市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のアデノシンデアミナーゼ-重症複合免疫不全症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 調査機関
• その他エンドユーザー
• 世界のアデノシンデアミナーゼ-重症複合免疫不全症市場酵素補充療法（ERT）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アデノシンデアミナーゼ酵素補充
• ペグ化エリスロポエチン（PEG-EPO）
• 世界のアデノシンデアミナーゼ-重症複合免疫不全症市場遺伝子治療の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 自家幹細胞を用いた遺伝子治療
• ウイルスベクターを介した遺伝子治療
• 世界のアデノシンデアミナーゼ-重症複合免疫不全症市場幹細胞移植の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• HLA適合骨髄移植
• 臍帯血移植
• 世界のアデノシンデアミナーゼ-重症複合免疫不全症市場支持療法の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗菌療法
• 免疫システムのサポート
• 栄養サポート

第7章 地域別・国別分析

• 世界のアデノシンデアミナーゼ-重症複合免疫不全症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のアデノシンデアミナーゼ-重症複合免疫不全症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• アデノシンデアミナーゼ-重症複合免疫不全症市場：競合情勢
• アデノシンデアミナーゼ-重症複合免疫不全症市場：企業プロファイル
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc（GSK）Overview, Products and Services, Strategy and Financial Analysis
  • Astellas Pharma Overview, Products and Services, Strategy and Financial Analysis
  • Orient EuroPharma Overview, Products and Services, Strategy and Financial Analysis
  • Charles River Laboratories Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Chiesi Farmaceutici S.p.A.
• Spark Therapeutics
• Rocket Pharmaceuticals
• Bluebird Bio
• Ospedale San Raffaele（OSR）
• Oxford Biomedica PLC
• Teijin Pharma
• Leadiant Biosciences
• Orchard Therapeutics PLC
• Fondazione Telethon
• Mustang Bio Inc
• Sigma-Tau Pharmaceuticals
• Shenzhen Geno-Immune Medical Institute
• ENZON Pharmaceuticals
• QED Bioscience Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• アデノシンデアミナーゼ-重症複合免疫不全症市場2029：新たな機会を提供する国
• アデノシンデアミナーゼ-重症複合免疫不全症市場2029：新たな機会を提供するセグメント
• アデノシンデアミナーゼ-重症複合免疫不全症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Adenosine deaminase-severe combined immunodeficiency (ADA-SCID) is a rare genetic disorder caused by a deficiency of the enzyme adenosine deaminase, resulting in the toxic accumulation of metabolites that hinder immune cell development. Understanding ADA-SCID is crucial for early diagnosis and management to prevent life-threatening infections and complications.

The primary treatment options for ADA-SCID include enzyme replacement therapy (ERT), gene therapy, stem cell transplantation, and supportive care. ERT involves administering synthetic or recombinant enzymes to compensate for the deficient or absent enzyme in individuals with genetic disorders. These therapies are delivered through various routes, including intravenous, subcutaneous, and oral administration. Designed for both pediatric and adult patients, they are distributed through hospital, retail, and online pharmacies. Key end-users include hospitals, specialty clinics, research institutes, and other healthcare facilities.

The adenosine deaminase-severe combined immunodeficiency market research report is one of a series of new reports from The Business Research Company that provides adenosine deaminase-severe combined immunodeficiency market statistics, including the adenosine deaminase-severe combined immunodeficiency industry global market size, regional shares, competitors with the adenosine deaminase-severe combined immunodeficiency market share, detailed adenosine deaminase-severe combined immunodeficiency market segments, market trends, and opportunities, and any further data you may need to thrive in the adenosine deaminase-severe combined immunodeficiency industry. This adenosine deaminase-severe combined immunodeficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The adenosine deaminase-severe combined immunodeficiency market size has grown strongly in recent years. It will grow from $5.57 billion in 2024 to $5.95 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth during the historic period can be attributed to the rising prevalence of severe combined immunodeficiency, an increasing incidence of primary immunodeficiencies (PID), a growing burden of immunodeficiency disorders, higher healthcare investments, and greater awareness of immunodeficiencies.

The adenosine deaminase-severe combined immunodeficiency market size is expected to see strong growth in the next few years. It will grow to $7.70 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period can be driven by the rising prevalence of genetic disorders, increased use of bone marrow transplantation, growing demand for non-conditioned stem cell transplantation, a higher prevalence of ADA deficiency, and a rising number of adenosine deaminase deficiency (PDA) cases. Key trends in this period include technological advancements, the adoption of gene therapy, government initiatives, advancements in genetic testing, and progress in biotechnology.

The increasing prevalence of genetic disorders is expected to drive the growth of the adenosine deaminase-severe combined immunodeficiency (ADA-SCID) market. Genetic disorders result from abnormalities or mutations in an individual's DNA, either inherited or occurring spontaneously. Factors such as advancements in diagnostic technologies, greater awareness, higher parental age, environmental influences, and population growth contribute to the rising prevalence of genetic conditions. In particular, the increasing occurrence of genetic disorders, including ADA-SCID, is fueling the demand for advanced diagnostic techniques and targeted treatments. For example, in December 2022, a report published by the Department of Health & Social Care (DHSC), a UK-based government department, revealed that as of October 2022, approximately 33,000 whole genome equivalents had been sequenced, with an average diagnostic yield of 32%, rising to 61% in specific conditions. Consequently, the growing prevalence of genetic disorders is propelling the expansion of the ADA-SCID market.

Leading companies in the ADA-SCID market are prioritizing the development of innovative treatments, such as gene therapy, to improve patient outcomes, enhance survival rates, and address the underlying genetic causes of the disorder using advanced medical technologies. Gene therapy for ADA-SCID aims to correct the genetic defect by introducing a functional copy of the ADA gene, potentially offering a long-term cure for this rare and life-threatening immune condition. For instance, in May 2022, Danaher Corporation, a US-based life sciences and diagnostics company, joined the Bespoke Gene Therapy Consortium (BGTC) as part of the Accelerating Medicines Partnership (AMP) program. This initiative, in collaboration with the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), pharmaceutical companies, and non-profit organizations, seeks to advance customized gene therapies for rare diseases and streamline their development. This collaboration is particularly important as it addresses the challenges of traditional drug development for rare diseases, which often receive limited commercial interest due to their low prevalence.

In January 2024, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company, acquired Orchard Therapeutics plc. for an undisclosed amount. This acquisition enhances Kyowa Kirin's focus on developing innovative treatments for rare and complex diseases by leveraging Orchard Therapeutics' expertise in gene therapy. Orchard Therapeutics plc, a UK-based company, specializes in creating gene therapies for rare genetic disorders.

Major players in the adenosine deaminase-severe combined immunodeficiency market are Novartis AG, GlaxoSmithKline plc (GSK), Astellas Pharma, Orient EuroPharma, Charles River Laboratories, Chiesi Farmaceutici S.p.A., Spark Therapeutics, Rocket Pharmaceuticals, Bluebird Bio, Ospedale San Raffaele (OSR), Oxford Biomedica PLC, Teijin Pharma, Leadiant Biosciences, Orchard Therapeutics PLC, Fondazione Telethon, Mustang Bio Inc., Sigma-Tau Pharmaceuticals, Shenzhen Geno-Immune Medical Institute, ENZON Pharmaceuticals, and QED Bioscience Inc.

North America was the largest region in the adenosine deaminase-severe combined immunodeficiency market in 2024. The regions covered in adenosine deaminase-severe combined immunodeficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the adenosine deaminase-severe combined immunodeficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The adenosine deaminase-severe combined immunodeficiency market consists of revenues earned by entities by providing services such as diagnosis and genetic testing, therapy services, and consultation & genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The adenosine deaminase-severe combined immunodeficiency market also includes sales of diagnostic tools, supportive therapies, and genetic testing kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adenosine Deaminase-Severe Combined Immunodeficiency Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adenosine deaminase-severe combined immunodeficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for adenosine deaminase-severe combined immunodeficiency ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adenosine deaminase-severe combined immunodeficiency market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Enzyme Replacement Therapy (ERT); Gene Therapy; Stem Cell Transplantation; Supportive Care Treatments
• 2) By Route of Administration: Intravenous; Subcutaneous; Oral
• 3) By Age Group: Pediatric (Infants and Children); Adults
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By End-User: Hospitals; Specialty Clinics; Research Institutes; Others End-Users
• Subsegments:
• 1) By Enzyme Replacement Therapy (ERT): Adenosine Deaminase Enzyme Replacement; Pegylated Erythropoietin (PEG-EPO)
• 2) By Gene Therapy: Autologous Stem Cell-Based Gene Therapy; Viral Vector-Mediated Gene Therapy
• 3) By Stem Cell Transplantation: HLA-Matched Bone Marrow Transplant; Umbilical Cord Blood Transplant
• 4) By Supportive Care Treatments: Antimicrobial Therapy; Immune System Support; Nutritional Support
• Companies Mentioned: Novartis AG; GlaxoSmithKline plc (GSK); Astellas Pharma; Orient EuroPharma; Charles River Laboratories
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Adenosine Deaminase-Severe Combined Immunodeficiency Market Characteristics

3. Adenosine Deaminase-Severe Combined Immunodeficiency Market Trends And Strategies

4. Adenosine Deaminase-Severe Combined Immunodeficiency Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Adenosine Deaminase-Severe Combined Immunodeficiency Growth Analysis And Strategic Analysis Framework

• 5.1. Global Adenosine Deaminase-Severe Combined Immunodeficiency PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market Growth Rate Analysis
• 5.4. Global Adenosine Deaminase-Severe Combined Immunodeficiency Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Adenosine Deaminase-Severe Combined Immunodeficiency Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Adenosine Deaminase-Severe Combined Immunodeficiency Total Addressable Market (TAM)

6. Adenosine Deaminase-Severe Combined Immunodeficiency Market Segmentation

• 6.1. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enzyme Replacement Therapy (ERT)
• Gene Therapy
• Stem Cell Transplantation
• Supportive Care Treatments
• 6.2. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Subcutaneous
• Oral
• 6.3. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric (Infants and Children)
• Adults
• 6.4. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Research Institutes
• Others End-User
• 6.6. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Sub-Segmentation Of Enzyme Replacement Therapy (ERT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adenosine Deaminase Enzyme Replacement
• Pegylated Erythropoietin (PEG-EPO)
• 6.7. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autologous Stem Cell-Based Gene Therapy
• Viral Vector-Mediated Gene Therapy
• 6.8. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Sub-Segmentation Of Stem Cell Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HLA-Matched Bone Marrow Transplant
• Umbilical Cord Blood Transplant
• 6.9. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Sub-Segmentation Of Supportive Care Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antimicrobial Therapy
• Immune System Support
• Nutritional Support

7. Adenosine Deaminase-Severe Combined Immunodeficiency Market Regional And Country Analysis

• 7.1. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 8.1. Asia-Pacific Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 9.1. China Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 9.2. China Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 10.1. India Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 11.1. Japan Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 11.2. Japan Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 12.1. Australia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 13.1. Indonesia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 14.1. South Korea Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 14.2. South Korea Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 15.1. Western Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 15.2. Western Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 16.1. UK Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 17.1. Germany Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 18.1. France Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 19.1. Italy Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 20.1. Spain Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 21.1. Eastern Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 21.2. Eastern Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 22.1. Russia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 23.1. North America Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 23.2. North America Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 24.1. USA Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 24.2. USA Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 25.1. Canada Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 25.2. Canada Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 26.1. South America Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 26.2. South America Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 27.1. Brazil Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 28.1. Middle East Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 28.2. Middle East Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 29.1. Africa Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 29.2. Africa Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Adenosine Deaminase-Severe Combined Immunodeficiency Market Competitive Landscape And Company Profiles

• 30.1. Adenosine Deaminase-Severe Combined Immunodeficiency Market Competitive Landscape
• 30.2. Adenosine Deaminase-Severe Combined Immunodeficiency Market Company Profiles
  • 30.2.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GlaxoSmithKline plc (GSK) Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Astellas Pharma Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Orient EuroPharma Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Charles River Laboratories Overview, Products and Services, Strategy and Financial Analysis

31. Adenosine Deaminase-Severe Combined Immunodeficiency Market Other Major And Innovative Companies

• 31.1. Chiesi Farmaceutici S.p.A.
• 31.2. Spark Therapeutics
• 31.3. Rocket Pharmaceuticals
• 31.4. Bluebird Bio
• 31.5. Ospedale San Raffaele (OSR)
• 31.6. Oxford Biomedica PLC
• 31.7. Teijin Pharma
• 31.8. Leadiant Biosciences
• 31.9. Orchard Therapeutics PLC
• 31.10. Fondazione Telethon
• 31.11. Mustang Bio Inc
• 31.12. Sigma-Tau Pharmaceuticals
• 31.13. Shenzhen Geno-Immune Medical Institute
• 31.14. ENZON Pharmaceuticals
• 31.15. QED Bioscience Inc.

32. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Adenosine Deaminase-Severe Combined Immunodeficiency Market

34. Recent Developments In The Adenosine Deaminase-Severe Combined Immunodeficiency Market

35. Adenosine Deaminase-Severe Combined Immunodeficiency Market High Potential Countries, Segments and Strategies

• 35.1 Adenosine Deaminase-Severe Combined Immunodeficiency Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Adenosine Deaminase-Severe Combined Immunodeficiency Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Adenosine Deaminase-Severe Combined Immunodeficiency Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer